Compare GREE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GREE | CING |
|---|---|---|
| Founded | 1937 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 26.8M |
| IPO Year | N/A | 2021 |
| Metric | GREE | CING |
|---|---|---|
| Price | $1.64 | $4.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 254.7K | 140.5K |
| Earning Date | 03-31-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,115,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $3.20 |
| 52 Week High | $2.42 | $6.01 |
| Indicator | GREE | CING |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 66.49 |
| Support Level | $1.45 | $3.85 |
| Resistance Level | $1.75 | $4.30 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 55.88 | 73.08 |
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center. Company operates in three segments: Crypto Mining, Datacenter Hosting, Power and Capacity. The company owns and operates facilities at two locations: the Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.